- $414.19m
- $430.92m
- $185.36m
- 96
- 72
- 81
- 96
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 14.28 | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | -11% | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | 17.14 | ||
| Price to Sales | 2.23 | ||
| EV to EBITDA | 13.61 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 21.53% | ||
| Return on Equity | n/a | ||
| Operating Margin | 15.46% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 109.98 | 116.57 | 139.4 | 164.96 | 185.36 | 201.72 | 233.76 | 13.94% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | +36.99 | -2.61 | n/a | n/a | -33.78 | +60.99 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
biote Corp. operates a practice-building business within the hormone optimization space. The Company provides the necessary components to enable Biote-certified practitioners to establish, build and implement a program designed to optimize hormone levels using personalized solutions for their patient populations. The Biote Method is a comprehensive, end-to-end practice building platform that provides Biote-certified practitioners with the components specifically developed for practitioners in the hormone optimization space: Biote Method education, training and certification, practice management software, inventory management software, and information regarding available hormone replacement therapy (HRT) products, as well as digital and point-of-care marketing support. It also sells a complementary Biote-branded line of dietary supplements. The Biote Method’s proprietary clinical decision support (CDS) software assists physicians in establishing individualized dosing for patients.
Directors
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- July 6th, 2020
- Public Since
- March 2nd, 2021
- No. of Shareholders
- 45
- No. of Employees
- 194
- Sector
- Professional & Commercial Services
- Industry
- Industrials
- Exchange
NASDAQ Global Market- Shares in Issue
- 75,033,876
- Address
- 1875 W. Walnut Hill Ln #100, Floor 5, IRVING, 75038
- Web
- https://haymakeracquisition.com/
- Phone
- +1 9724869346
- Auditors
- Deloitte & Touche LLP
Upcoming Events for BTMD
Q1 2024 Biote Corp Earnings Call
Similar to BTMD
CompoSecure
NASDAQ Global Market
ESGL Holdings
NASDAQ Global Market
Kewaunee Scientific
NASDAQ Global Market
MarketWise
NASDAQ Global Market
Onemednet
NASDAQ Global Market
FAQ
What is the biote share price?
As of Today at 19:03 UTC, shares in biote are trading at $5.52. This share price information is delayed by 15 minutes.
How has the biote share price performed this year?
Shares in biote last closed at $5.52 and the price had moved by -9.8% over the past 365 days. In terms of relative price strength the biote share price has underperformed the S&P500 Index by -26.26% over the past year.
What are the analyst and broker recommendations for biote?
The overall consensus recommendation for biote is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the biote dividend yield?
biote does not currently pay a dividend.
Does biote pay a dividend?
biote does not currently pay a dividend.
When does biote next pay dividends?
biote does not currently pay a dividend.
How do I buy biote shares?
To buy shares in biote you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of biote?
As of the previous close price of $5.52, shares in biote had a market capitalisation of $414.19m.
Where are biote shares listed?
Here are the trading details for biote:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: BTMD
What kind of share is biote?
Based on an overall assessment of its quality, value and momentum biote is currently classified as a Super Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a biote share price forecast for 2024?
The analyst consensus target price for shares in biote is $8.65. That is 56.7% above the last closing price of $5.52.
Analysts covering biote currently have a consensus Earnings Per Share (EPS) forecast of $0.32 for the next financial year.
What is the trend in the biote share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like biote. Over the past six months, its share price has underperformed the S&P500 Index by -11.74%.
As of the last closing price of $5.52, shares in biote were trading +3.13% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the biote PE Ratio?
The biote PE ratio based on its reported earnings over the past 12 months is 14.28. The shares last closed at $5.52.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of biote?
We do not have data on biote's directors